Evaluation of Neoven Capsules Containing Ruscus Aculeatus L for Treating Stage II-III Hemorrhoids in Adults Aged 18 to 45

What this Trial Is About

Researchers are studying the effects of Ruscus aculeatus L., a plant known for its vasoconstrictor, diuretic, anti-inflammatory, and venotonic properties, on patients with stage II-III hemorrhoidal disease. Hemorrhoidal disease involves deterioration of vascular cushions in the anal canal, causing symptoms like bleeding, discomfort, and pain. This research aims to provide scientific evidence on a new herbal treatment option for hemorrhoids. The study compares the use of Neoven 225 mg capsules containing Ruscus aculeatus L. with a placebo. Participants will take one capsule twice daily with meals for 42 days, receiving a total of 84 capsules. The active capsules contain a mixture of ruscogenin and neoruscogenin compounds. Capsule use will be monitored by phone calls on days 7 and 14, and pill counts at the end of treatment. Participants will be evaluated for quality of life using the Hemorrhoid Severity Score at the end of 42 days. Additional assessments include the Hemorrhoidal Disease Symptom Score and a Visual Analog Scale for symptoms. Researchers will monitor adherence to treatment and the safety of the herbal product throughout the study period, which is led by Sultan Abdulhamid Han Training and Research Hospital.

Efficacy and Safety Evaluation of Ruscus Aculeatus L in Patients With Hemorrhoids